MeSH term
Frequency | Condition_Probility | Female | 539 | 0.0 |
Humans | 1384 | 0.0 |
Pregnancy | 49 | 0.0 |
Randomized Controlled Trials | 3 | 0.0 |
Acute Disease | 19 | 0.0 |
Adult | 309 | 0.0 |
Comparative Study | 130 | 0.0 |
Cell Culture Techniques | 2 | 0.0 |
Animals | 208 | 0.0 |
Antioxidants/*metabolism | 6 | 6.0 |
Enzyme Inhibitors/pharmacology | 3 | 0.0 |
Erythrocytes/drug effects/enzymology | 3 | 10.0 |
Glucosephosphate Dehydrogenase/antagonists & inhibitors/*metabolism | 3 | 100.0 |
Male | 799 | 0.0 |
Rats | 29 | 0.0 |
Statistics, Nonparametric | 2 | 0.0 |
Erythrocytes/chemistry/*enzymology | 2 | 66.0 |
Glucosephosphate Dehydrogenase/*blood | 71 | 95.0 |
Hexokinase/*blood | 3 | 60.0 |
Middle Aged | 168 | 0.0 |
NADP/metabolism | 29 | 23.0 |
Reference Values | 26 | 0.0 |
Thyrotropin/blood | 3 | 0.0 |
Zinc/*blood | 3 | 12.0 |
Enzyme Activation/drug effects | 8 | 0.0 |
Erythrocytes/*drug effects/enzymology | 4 | 36.0 |
Glucosephosphate Dehydrogenase/*metabolism | 55 | 96.0 |
In Vitro | 29 | 0.0 |
Rats, Sprague-Dawley | 6 | 0.0 |
Gene Frequency | 74 | 1.0 |
Genotype | 27 | 0.0 |
Glucosephosphate Dehydrogenase/genetics/*metabolism | 9 | 100.0 |
Glucuronosyltransferase/*genetics | 6 | 5.0 |
Homozygote | 28 | 1.0 |
Infant, Newborn | 165 | 3.0 |
Mutation | 68 | 0.0 |
Research Support, Non-U.S. Gov't | 587 | 0.0 |
Adolescent | 142 | 0.0 |
Aged | 81 | 0.0 |
Calcium/blood | 4 | 1.0 |
Child | 167 | 1.0 |
Erythrocytes/*metabolism | 26 | 12.0 |
Glutathione Reductase/*blood | 6 | 66.0 |
NADP/*blood | 4 | 57.0 |
Oxidation-Reduction | 51 | 3.0 |
Erythrocytes/drug effects/metabolism | 3 | 21.0 |
Glucosephosphate Dehydrogenase/blood/genetics | 6 | 100.0 |
Glucosephosphate Dehydrogenase Deficiency/*blood | 52 | 100.0 |
Prospective Studies | 12 | 0.0 |
Research Support, U.S. Gov't, P.H.S. | 240 | 0.0 |
Tetradecanoylphorbol Acetate/pharmacology | 2 | 0.0 |
Base Sequence | 121 | 0.0 |
DNA Primers | 13 | 0.0 |
Glucosephosphate Dehydrogenase Deficiency/*epidemiology | 23 | 95.0 |
Incidence | 32 | 2.0 |
DNA Mutational Analysis/methods | 3 | 1.0 |
European Continental Ancestry Group | 7 | 1.0 |
Genetic Heterogeneity | 3 | 1.0 |
Glucosephosphate Dehydrogenase/*genetics | 185 | 97.0 |
Glucosephosphate Dehydrogenase Deficiency/epidemiology/*genetics | 22 | 100.0 |
Haplotypes | 15 | 0.0 |
Portugal/epidemiology | 2 | 11.0 |
DNA Mutational Analysis | 34 | 0.0 |
Glucosephosphate Dehydrogenase Deficiency/complications/genetics | 2 | 100.0 |
Glucuronosyltransferase/genetics | 3 | 18.0 |
Membrane Proteins/genetics | 3 | 0.0 |
Promoter Regions (Genetics)/genetics | 3 | 0.0 |
Variation (Genetics) | 74 | 4.0 |
Glucosephosphate Dehydrogenase/metabolism | 40 | 75.0 |
Glutathione/metabolism | 21 | 10.0 |
Glycolysis | 7 | 13.0 |
Hemolysis | 24 | 7.0 |
Magnetic Resonance Spectroscopy | 2 | 0.0 |
*Pentosephosphate Pathway | 4 | 80.0 |
Time Factors | 36 | 0.0 |
Antimalarials/*therapeutic use | 6 | 20.0 |
Host-Parasite Relations | 2 | 5.0 |
Liver Function Tests | 5 | 2.0 |
Predictive Value of Tests | 5 | 0.0 |
Prognosis | 8 | 0.0 |
Thailand | 6 | 4.0 |
Anemia, Hemolytic/chemically induced | 3 | 75.0 |
Hematocrit | 14 | 3.0 |
Antineoplastic Agents, Alkylating/*pharmacology | 2 | 5.0 |
Apoptosis/drug effects | 2 | 0.0 |
Dose-Response Relationship, Drug | 13 | 0.0 |
Drug Interactions | 2 | 0.0 |
Flow Cytometry | 9 | 0.0 |
Glucosephosphate Dehydrogenase/genetics | 82 | 90.0 |
Polymerase Chain Reaction | 70 | 0.0 |
Chromatography, Affinity | 2 | 0.0 |
Chromatography, Gel | 2 | 0.0 |
Electrophoresis, Polyacrylamide Gel | 18 | 0.0 |
Enzyme Inhibitors/*pharmacology | 2 | 0.0 |
Erythrocytes/*enzymology | 116 | 22.0 |
Glucosephosphate Dehydrogenase/*antagonists & inhibitors | 4 | 100.0 |
Blood Cell Count | 7 | 2.0 |
Glucosephosphate Dehydrogenase Deficiency/*complications | 61 | 98.0 |
Hemoglobins/metabolism | 6 | 3.0 |
Hemolysis/*drug effects | 16 | 42.0 |
Erythrocyte Count | 11 | 11.0 |
Favism/complications | 2 | 100.0 |
Pilot Projects | 2 | 0.0 |
Blood Chemical Analysis | 3 | 6.0 |
Dogs | 7 | 0.0 |
Glucosephosphate Dehydrogenase/analysis | 14 | 93.0 |
Glutathione/analysis | 2 | 15.0 |
Osmotic Fragility | 2 | 16.0 |
Case-Control Studies | 15 | 0.0 |
Erythrocytes/*physiology | 3 | 6.0 |
Glucosephosphate Dehydrogenase/genetics/metabolism | 6 | 100.0 |
Glucosephosphate Dehydrogenase Deficiency/genetics/*metabolism | 3 | 100.0 |
Methylation | 16 | 2.0 |
Point Mutation | 29 | 1.0 |
Blotting, Western | 9 | 0.0 |
DNA Primers/chemistry | 3 | 0.0 |
Erythrocytes/metabolism | 9 | 4.0 |
Glyceraldehyde-3-Phosphate Dehydrogenases/metabolism | 3 | 14.0 |
L-Lactate Dehydrogenase/metabolism | 7 | 4.0 |
Phosphogluconate Dehydrogenase/metabolism | 7 | 63.0 |
Reverse Transcriptase Polymerase Chain Reaction | 4 | 0.0 |
Crystallization | 2 | 0.0 |
Free Radicals/metabolism | 2 | 3.0 |
*Lipid Peroxidation | 2 | 4.0 |
Haplotypes/genetics | 5 | 0.0 |
India/ethnology | 2 | 2.0 |
Iran/ethnology | 2 | 25.0 |
Neonatal Screening | 6 | 19.0 |
Prenatal Diagnosis | 4 | 2.0 |
Prevalence | 40 | 3.0 |
Sequence Deletion | 4 | 0.0 |
Mass Screening | 13 | 7.0 |
Glucosephosphate Dehydrogenase Deficiency/*complications/diagnosis | 4 | 100.0 |
Hepatitis A/*complications/diagnosis | 3 | 100.0 |
Severity of Illness Index | 6 | 0.0 |
Heterozygote | 91 | 3.0 |
Pyruvate Kinase/*blood | 4 | 50.0 |
Amino Acid Substitution | 10 | 0.0 |
China | 18 | 3.0 |
Deoxyribonucleases, Type II Site-Specific/metabolism | 3 | 1.0 |
English Abstract | 100 | 0.0 |
Glucosephosphate Dehydrogenase Deficiency/enzymology/*genetics | 19 | 95.0 |
Polymorphism, Genetic | 51 | 1.0 |
China/ethnology | 13 | 6.0 |
*Mutation | 52 | 1.0 |
Glucosephosphate Dehydrogenase Deficiency/genetics | 30 | 93.0 |
*Linkage (Genetics) | 19 | 1.0 |
*Point Mutation | 42 | 3.0 |
*Polymorphism, Genetic | 51 | 1.0 |
Kinetics | 85 | 1.0 |
Mutation/*genetics | 6 | 0.0 |
Child, Preschool | 102 | 1.0 |
Hemolysis/*genetics | 2 | 50.0 |
Japan | 16 | 1.0 |
Hydrogen-Ion Concentration | 39 | 3.0 |
Liver/*enzymology | 3 | 0.0 |
Antimalarials/adverse effects | 2 | 100.0 |
Follow-Up Studies | 8 | 0.0 |
Glucosephosphate Dehydrogenase Deficiency/*complications/genetics | 11 | 100.0 |
Drug Administration Schedule | 2 | 0.0 |
Treatment Outcome | 11 | 0.0 |
Jurkat Cells | 3 | 0.0 |
Mice | 73 | 0.0 |
Mice, Inbred C57BL | 7 | 0.0 |
RNA, Messenger/genetics | 5 | 0.0 |
*Transcription, Genetic | 5 | 0.0 |
Tumor Cells, Cultured | 20 | 0.0 |
*Variation (Genetics) | 73 | 7.0 |
Chromosome Mapping | 50 | 0.0 |
Evolution, Molecular | 5 | 0.0 |
Molecular Sequence Data | 120 | 0.0 |
Polymorphism, Single Nucleotide | 2 | 0.0 |
Sequence Analysis, DNA | 13 | 0.0 |
Anemia, Hemolytic/*chemically induced/physiopathology | 2 | 100.0 |
Carcinogens | 2 | 2.0 |
*Glucosephosphate Dehydrogenase Deficiency | 8 | 100.0 |
Occupational Exposure | 2 | 2.0 |
Glucosephosphate Dehydrogenase Deficiency/complications | 11 | 100.0 |
Nitrites/*adverse effects | 2 | 100.0 |
Hemolysis/drug effects | 9 | 15.0 |
Asian Continental Ancestry Group/*genetics | 6 | 1.0 |
Gene Frequency/*genetics | 3 | 2.0 |
Genetic Screening | 6 | 0.0 |
Glucosephosphate Dehydrogenase/*genetics/metabolism | 33 | 100.0 |
Amino Acid Substitution/genetics | 2 | 0.0 |
Automation | 2 | 3.0 |
Conserved Sequence/genetics | 2 | 1.0 |
DNA/metabolism | 9 | 0.0 |
Hydrogen Bonding | 2 | 1.0 |
Models, Molecular | 12 | 0.0 |
Protein Binding | 3 | 0.0 |
Protein Folding | 2 | 0.0 |
Protein Structure, Tertiary | 3 | 0.0 |
Structure-Activity Relationship | 10 | 0.0 |
CHO Cells | 2 | 0.0 |
Cell Nucleus/metabolism | 5 | 0.0 |
Chromatography, High Pressure Liquid | 7 | 0.0 |
DNA Damage | 3 | 0.0 |
*DNA Helicases | 2 | 0.0 |
DNA Repair | 2 | 0.0 |
Dithiothreitol/pharmacology | 2 | 2.0 |
Hamsters | 27 | 0.0 |
Models, Chemical | 2 | 0.0 |
NAD/metabolism | 4 | 6.0 |
*Oxidative Stress | 11 | 4.0 |
Transfection | 8 | 0.0 |
Anemia, Hemolytic/*etiology | 15 | 88.0 |
Chronic Disease | 21 | 1.0 |
Mutation, Missense | 7 | 0.0 |
African Americans | 4 | 3.0 |
Glucosephosphate Dehydrogenase/*blood/genetics | 8 | 100.0 |
*Mutation, Missense | 5 | 0.0 |
Nitric-Oxide Synthase/blood | 2 | 40.0 |
Consanguinity | 9 | 2.0 |
Continental Population Groups | 10 | 5.0 |
Geography | 3 | 4.0 |
Glucosephosphate Dehydrogenase Deficiency/ethnology/*genetics | 4 | 100.0 |
Heterozygote Detection | 17 | 3.0 |
India/epidemiology | 13 | 14.0 |
Polymorphism, Genetic/*genetics | 4 | 0.0 |
Cattle | 7 | 0.0 |
Cell Line | 39 | 0.0 |
Culture Media | 4 | 0.0 |
Fertilization in Vitro | 3 | 2.0 |
Linkage (Genetics)/genetics | 2 | 0.0 |
Phosphoglycerate Kinase/*genetics | 2 | 9.0 |
Transcription Factors/*genetics | 3 | 0.0 |
X Chromosome/*genetics | 5 | 1.0 |
Ethnic Groups/genetics | 3 | 1.0 |
Myanmar | 4 | 44.0 |
Asian Continental Ancestry Group | 11 | 3.0 |
Ethnic Groups | 14 | 5.0 |
Glucosephosphate Dehydrogenase Deficiency/*genetics | 93 | 95.0 |
Glucosephosphate Dehydrogenase/blood | 57 | 90.0 |
Glucosephosphate Dehydrogenase Deficiency/blood/*enzymology | 4 | 100.0 |
Rabbits/immunology | 3 | 3.0 |
Cytoplasm/enzymology | 4 | 5.0 |
Endoplasmic Reticulum/enzymology/ultrastructure | 2 | 66.0 |
Ferrocyanides | 2 | 100.0 |
Gestational Age | 9 | 1.0 |
Glucosephosphate Dehydrogenase/*analysis/metabolism | 2 | 100.0 |
*Histocytochemistry | 3 | 50.0 |
Indicators and Reagents | 4 | 1.0 |
Microscopy, Electron | 10 | 0.0 |
Chemoprevention | 2 | 4.0 |
Drug Combinations | 2 | 0.0 |
Indonesia | 6 | 24.0 |
Malaria, Falciparum/blood/*prevention & control | 2 | 100.0 |
Naphthoquinones/therapeutic use | 2 | 66.0 |
Plasmodium falciparum/drug effects | 2 | 100.0 |
Primaquine/*therapeutic use | 2 | 100.0 |
Research Support, U.S. Gov't, Non-P.H.S. | 44 | 0.0 |
Nucleic Acid Amplification Techniques/methods | 4 | 33.0 |
Alleles | 49 | 0.0 |
Polymerase Chain Reaction/methods | 14 | 1.0 |
Anemia, Hemolytic, Congenital/*genetics | 4 | 57.0 |
Family Health | 6 | 0.0 |
Anemia, Hemolytic/*chemically induced | 13 | 100.0 |
Antimalarials/*adverse effects | 2 | 100.0 |
Glucosephosphate Dehydrogenase Deficiency/complications/*diagnosis | 3 | 100.0 |
Malaria/complications | 3 | 50.0 |
Reagent Kits, Diagnostic/standards | 2 | 12.0 |
RNA Splicing | 4 | 0.0 |
Iraq/epidemiology | 4 | 80.0 |
Phenotype | 95 | 1.0 |
Antimalarials/administration & dosage/*adverse effects | 2 | 66.0 |
*Hemolysis | 19 | 22.0 |
Anemia/blood | 2 | 8.0 |
Glucosephosphate Dehydrogenase Deficiency/blood/genetics | 3 | 100.0 |
Hemoglobins/*analysis | 2 | 3.0 |
Iraq | 3 | 42.0 |
Mutation/genetics | 10 | 0.0 |
Reticulocytes | 3 | 9.0 |
X Chromosome/genetics | 8 | 4.0 |
Hemoglobins/analysis | 18 | 6.0 |
Reticulocyte Count | 3 | 8.0 |
Cohort Studies | 10 | 0.0 |
Risk Factors | 24 | 0.0 |
Taiwan/epidemiology | 6 | 5.0 |
Metabolic Detoxication, Drug | 2 | 2.0 |
Promoter Regions (Genetics) | 4 | 0.0 |
RNA, Messenger/analysis | 5 | 0.0 |
Glucosephosphate Dehydrogenase/*analysis | 15 | 100.0 |
Histocytochemistry | 20 | 3.0 |
Antioxidants/*pharmacology | 2 | 1.0 |
Ultraviolet Rays/*adverse effects | 2 | 4.0 |
Brazil/epidemiology | 2 | 2.0 |
Enzyme Tests | 2 | 2.0 |
Glucosephosphate Dehydrogenase Deficiency/diagnosis/*epidemiology | 3 | 75.0 |
*Neonatal Screening | 9 | 36.0 |
Enzyme Tests/methods | 2 | 28.0 |
*Health Education | 2 | 28.0 |
Infant | 62 | 1.0 |
Jaundice, Neonatal/epidemiology/etiology | 2 | 100.0 |
Thailand/epidemiology | 3 | 5.0 |
Glucosephosphate Dehydrogenase Deficiency/*diagnosis/epidemiology | 5 | 100.0 |
Singapore/epidemiology | 8 | 25.0 |
Glucose-6-Phosphatase/blood | 2 | 100.0 |
Fatty Acids/metabolism | 2 | 1.0 |
Retrospective Studies | 14 | 0.0 |
Codon/genetics | 2 | 0.0 |
Ethnic Groups/*genetics | 7 | 3.0 |
Malaria/epidemiology | 5 | 55.0 |
Selection (Genetics) | 13 | 9.0 |
Aged, 80 and over | 10 | 0.0 |
Erythrocytes/enzymology | 97 | 24.0 |
*Diet | 2 | 0.0 |
*Gene Expression Regulation, Enzymologic | 2 | 0.0 |
African Continental Ancestry Group/*genetics | 10 | 3.0 |
Glucosephosphate Dehydrogenase Deficiency/*complications/*genetics | 2 | 100.0 |
Chromosome Aberrations | 8 | 1.0 |
Epidemiologic Studies | 2 | 4.0 |
Infection/complications | 4 | 30.0 |
Chloroquine/administration & dosage/*adverse effects | 2 | 100.0 |
Drug Therapy, Combination | 2 | 0.0 |
Glucosephosphate Dehydrogenase Deficiency/blood/*complications | 11 | 91.0 |
Rural Health | 3 | 16.0 |
Phototherapy | 7 | 46.0 |
Risk | 10 | 1.0 |
Sex Factors | 26 | 1.0 |
Spectrophotometry | 6 | 3.0 |
Placenta/*enzymology | 3 | 3.0 |
Substrate Specificity | 9 | 0.0 |
Africa | 9 | 10.0 |
Europe | 5 | 1.0 |
Glutathione/*blood | 7 | 43.0 |
Hypertension/*blood | 3 | 4.0 |
Oxidative Stress | 8 | 2.0 |
Pedigree | 69 | 1.0 |
Sensitivity and Specificity | 11 | 0.0 |
Sex Distribution | 5 | 1.0 |
Variation (Genetics)/genetics | 4 | 2.0 |
Erythrocyte Membrane/*metabolism | 3 | 4.0 |
Molecular Weight | 3 | 0.0 |
Thermodynamics | 4 | 1.0 |
Anemia, Hemolytic/complications | 2 | 50.0 |
Italy/epidemiology | 14 | 6.0 |
Cell Survival/drug effects | 2 | 0.0 |
Dehydroepiandrosterone/*pharmacology | 3 | 27.0 |
ABO Blood-Group System/genetics | 5 | 11.0 |
Amino Acid Sequence | 47 | 0.0 |
Antigens, Protozoan/genetics | 2 | 28.0 |
DNA Primers/genetics | 8 | 0.0 |
Hemoglobins/genetics | 7 | 28.0 |
Sickle Cell Trait/genetics | 2 | 100.0 |
Tumor Necrosis Factor-alpha/genetics | 2 | 0.0 |
Adaptation, Physiological | 4 | 4.0 |
Cells, Cultured | 52 | 0.0 |
Cytoplasm/metabolism | 2 | 0.0 |
Exons | 21 | 0.0 |
Gene Expression Regulation | 11 | 0.0 |
Introns | 5 | 0.0 |
Liver/metabolism | 2 | 0.0 |
RNA, Messenger/*metabolism | 2 | 0.0 |
Jews/*genetics | 3 | 2.0 |
3T3 Cells | 3 | 0.0 |
DNA, Complementary/genetics | 8 | 0.0 |
Enzyme Induction | 4 | 0.0 |
Genetic Complementation Test | 2 | 0.0 |
Transcription, Genetic | 14 | 0.0 |
Asian Continental Ancestry Group/genetics | 4 | 1.0 |
Glucosephosphate Dehydrogenase/blood/*genetics | 36 | 100.0 |
Glucosephosphate Dehydrogenase Deficiency/*diagnosis | 10 | 100.0 |
Immunoglobulin G/metabolism | 3 | 1.0 |
Malaria, Falciparum/*immunology | 2 | 13.0 |
Pakistan/epidemiology | 2 | 15.0 |
CpG Islands/genetics | 2 | 1.0 |
DNA Replication/*genetics | 2 | 3.0 |
*Dosage Compensation (Genetics) | 11 | 6.0 |
Fibroblasts | 8 | 1.0 |
Phosphoglycerate Kinase/genetics | 9 | 24.0 |
Cell Division/drug effects | 8 | 0.0 |
K562 Cells | 2 | 0.0 |
Anemia, Sickle Cell/complications | 2 | 50.0 |
*Cell Aging | 2 | 3.0 |
Cell Cycle | 3 | 0.0 |
Cell Division | 11 | 0.0 |
Reactive Oxygen Species/metabolism | 2 | 0.0 |
Diagnosis, Differential | 12 | 0.0 |
Reference Standards | 3 | 1.0 |
Dimerization | 4 | 0.0 |
Glucosephosphate Dehydrogenase/chemistry/*genetics | 5 | 100.0 |
*Glucosephosphate Dehydrogenase Deficiency/diagnosis/genetics | 2 | 100.0 |
Jaundice, Neonatal/enzymology | 2 | 100.0 |
Syndrome | 5 | 0.0 |
Blood Group Antigens/genetics | 7 | 11.0 |
*Gene Frequency | 18 | 3.0 |
Glucose/*metabolism | 3 | 1.0 |
Glucosephosphate Dehydrogenase Deficiency/*blood/complications | 10 | 90.0 |
Greece/epidemiology | 2 | 5.0 |
Reagent Kits, Diagnostic | 4 | 2.0 |
Rats, Wistar | 3 | 0.0 |
Primaquine/*adverse effects | 3 | 100.0 |
Sulfanilamides/*adverse effects | 2 | 100.0 |
Greece | 7 | 8.0 |
Polymorphism, Single-Stranded Conformational | 19 | 0.0 |
Binding Sites | 4 | 0.0 |
Germany | 2 | 0.0 |
Emigration and Immigration | 4 | 8.0 |
Endemic Diseases | 2 | 12.0 |
Glucosephosphate Dehydrogenase Deficiency/*epidemiology/ethnology | 3 | 100.0 |
Vietnam/epidemiology | 2 | 15.0 |
Glucosephosphate Dehydrogenase Deficiency/*blood/enzymology | 2 | 100.0 |
Nigeria | 7 | 11.0 |
Crystallography, X-Ray | 3 | 0.0 |
Glucosephosphate Dehydrogenase/*chemistry/genetics | 3 | 100.0 |
Glucosephosphate Dehydrogenase Deficiency/*enzymology | 21 | 100.0 |
Protein Conformation | 8 | 0.0 |
Sequence Homology, Amino Acid | 10 | 0.0 |
Glucosephosphate Dehydrogenase/chemistry/*metabolism | 2 | 100.0 |
Glucosephosphate Dehydrogenase Deficiency/*metabolism | 11 | 100.0 |
Protein Structure, Secondary | 2 | 0.0 |
Genetic Markers | 46 | 1.0 |
Horses/*genetics | 2 | 9.0 |
Hybrid Cells | 24 | 1.0 |
In Situ Hybridization, Fluorescence | 2 | 0.0 |
Pseudogenes | 2 | 1.0 |
*X Chromosome | 62 | 6.0 |
*Y Chromosome | 3 | 2.0 |
Pakistan | 2 | 5.0 |
Primaquine/*administration & dosage | 2 | 100.0 |
Recurrence | 3 | 0.0 |
Oxygen/*physiology | 2 | 9.0 |
*Sex Characteristics | 2 | 1.0 |
Blotting, Northern | 7 | 0.0 |
*Gene Expression Regulation, Neoplastic | 2 | 0.0 |
Gene Expression | 13 | 0.0 |
Linkage (Genetics) | 47 | 1.0 |
RNA, Messenger/metabolism | 7 | 0.0 |
*Evolution, Molecular | 3 | 0.0 |
Glucosephosphate Dehydrogenase/*chemistry/*genetics | 4 | 100.0 |
Sequence Alignment | 2 | 0.0 |
X Chromosome | 31 | 6.0 |
Chloroquine/therapeutic use | 4 | 26.0 |
Melanesia/epidemiology | 2 | 50.0 |
Primaquine/therapeutic use | 2 | 100.0 |
Erythrocytes/enzymology/*metabolism | 8 | 50.0 |
Hemoglobins/*metabolism | 3 | 7.0 |
Immunity, Natural/genetics | 3 | 4.0 |
Plasmodium falciparum | 5 | 14.0 |
Egypt | 2 | 4.0 |
Genetics, Population | 18 | 4.0 |
Glucosephosphate Dehydrogenase Deficiency/*epidemiology/*genetics | 3 | 100.0 |
Iran | 4 | 11.0 |
Jordan | 3 | 21.0 |
Kuwait | 3 | 12.0 |
Anemia, Hemolytic, Congenital Nonspherocytic/enzymology/*genetics | 4 | 100.0 |
Genomic Imprinting | 2 | 1.0 |
Anemia, Hemolytic/etiology | 5 | 41.0 |
Favism/*genetics | 2 | 100.0 |
Japan/epidemiology | 2 | 0.0 |
Taiwan/ethnology | 3 | 27.0 |
Biological Markers | 2 | 0.0 |
Cell Lineage | 2 | 0.0 |
Dosage Compensation (Genetics) | 16 | 11.0 |
Hematopoiesis | 6 | 2.0 |
Hypoxanthine Phosphoribosyltransferase/genetics | 16 | 20.0 |
Isoenzymes/genetics | 18 | 5.0 |
Receptors, Androgen/genetics | 2 | 3.0 |
T-Lymphocytes/pathology | 2 | 1.0 |
Glucosephosphate Dehydrogenase/blood/metabolism | 3 | 100.0 |
Calcium/*blood | 2 | 2.0 |
Copper/*blood | 2 | 15.0 |
Magnesium/*blood | 2 | 13.0 |
Glutathione Peroxidase/metabolism | 6 | 17.0 |
Glutathione Reductase/metabolism | 8 | 53.0 |
Glutathione Transferase/metabolism | 2 | 0.0 |
Glucosephosphate Dehydrogenase/*physiology | 2 | 100.0 |
History, 20th Century | 3 | 2.0 |
Population Dynamics | 2 | 25.0 |
Thalassemia/genetics | 2 | 25.0 |
Anemia, Hemolytic, Congenital Nonspherocytic/*enzymology/*genetics | 2 | 66.0 |
Favism/*enzymology/*genetics | 2 | 100.0 |
Glucosephosphate Dehydrogenase Deficiency/*enzymology/*genetics | 3 | 100.0 |
Poland | 3 | 2.0 |
Stem Cells/*pathology | 2 | 12.0 |
Age Factors | 18 | 0.0 |
Glucosephosphate Dehydrogenase Deficiency/parasitology | 2 | 100.0 |
Hemoglobin, Sickle | 2 | 40.0 |
Multivariate Analysis | 2 | 0.0 |
Nigeria/epidemiology | 8 | 25.0 |
Adenosine Deaminase/blood | 4 | 28.0 |
Adenylate Kinase/blood | 3 | 30.0 |
Birth Weight | 3 | 1.0 |
Catalase/blood | 4 | 19.0 |
Fetal Blood/*enzymology | 3 | 27.0 |
Glucose-6-Phosphate Isomerase/blood | 4 | 44.0 |
Glutathione Peroxidase/blood | 4 | 11.0 |
Glutathione Reductase/blood | 7 | 35.0 |
Phosphogluconate Dehydrogenase/blood | 12 | 70.0 |
Malaysia/epidemiology | 4 | 23.0 |
*Genetic Screening | 2 | 1.0 |
Health Surveys | 3 | 4.0 |
Rural Population | 8 | 8.0 |
Administration, Topical | 3 | 2.0 |
Enzyme Stability | 8 | 4.0 |
Drug Resistance | 5 | 0.0 |
Methemoglobin/analysis | 3 | 75.0 |
Quality Control | 3 | 1.0 |
Hematologic Tests | 3 | 8.0 |
Temperature | 8 | 0.0 |
Databases, Factual | 2 | 0.0 |
Fathers | 3 | 5.0 |
Glucosephosphate Dehydrogenase Deficiency/complications/*genetics | 12 | 100.0 |
Italy | 50 | 8.0 |
Mothers | 2 | 2.0 |
Sex Characteristics | 5 | 0.0 |
Evaluation Studies | 3 | 0.0 |
Tetrazolium Salts/*diagnostic use | 2 | 66.0 |
*Gene Expression | 2 | 0.0 |
Africa/ethnology | 4 | 8.0 |
Demography | 2 | 1.0 |
Ecuador | 2 | 18.0 |
Enzymes/genetics | 2 | 6.0 |
Phylogeny | 6 | 0.0 |
Isoenzymes/*genetics | 13 | 3.0 |
Mathematics | 5 | 2.0 |
alpha-Galactosidase/genetics | 5 | 83.0 |
Glucosephosphate Dehydrogenase Deficiency/epidemiology | 3 | 100.0 |
Bilirubin/*blood | 4 | 19.0 |
Gilbert Disease/*genetics | 3 | 27.0 |
Glucosephosphate Dehydrogenase Deficiency/blood/*genetics | 8 | 100.0 |
Mass Screening/*methods | 2 | 3.0 |
Reproducibility of Results | 6 | 0.0 |
Blood Transfusion | 5 | 2.0 |
Cloning, Molecular | 30 | 0.0 |
*Genome, Human | 2 | 0.0 |
Glucose Dehydrogenases/*genetics | 2 | 66.0 |
Rabbits | 7 | 0.0 |
Sequence Analysis | 2 | 0.0 |
Cell Differentiation | 8 | 0.0 |
Glucosephosphate Dehydrogenase Deficiency/diagnosis/*genetics | 3 | 100.0 |
Superoxide Dismutase/metabolism | 4 | 4.0 |
Electrophoresis | 19 | 6.0 |
Mutagenesis, Site-Directed | 9 | 0.0 |
DNA, Complementary | 2 | 0.0 |
DNA-Binding Proteins/*genetics | 2 | 0.0 |
Sequence Homology, Nucleic Acid | 14 | 0.0 |
Glucosephosphate Dehydrogenase/*biosynthesis/genetics | 4 | 100.0 |
Escherichia coli/genetics | 3 | 0.0 |
United Arab Emirates/epidemiology | 4 | 50.0 |
Hydrogen Peroxide/pharmacology | 5 | 2.0 |
Jaundice, Neonatal/*epidemiology/etiology | 2 | 100.0 |
Buthionine Sulfoximine/pharmacology | 2 | 5.0 |
Catalase/metabolism | 7 | 11.0 |
Diamide/pharmacology | 8 | 40.0 |
Glucosephosphate Dehydrogenase/*biosynthesis | 4 | 100.0 |
Glutathione/*metabolism | 8 | 13.0 |
Hela Cells | 4 | 0.0 |
European Continental Ancestry Group/genetics | 4 | 0.0 |
*Genetics, Population | 8 | 2.0 |
Polymorphism, Restriction Fragment Length | 15 | 0.0 |
Erythrocytes/*chemistry | 2 | 5.0 |
Immunity, Natural | 2 | 0.0 |
L-Lactate Dehydrogenase/blood | 7 | 6.0 |
Mexico | 2 | 2.0 |
Urban Health | 2 | 5.0 |
Erythrocytes/physiology | 2 | 5.0 |
Lipopolysaccharides/pharmacology | 2 | 0.0 |
Mediterranean Region | 2 | 9.0 |
Phagocytosis | 2 | 0.0 |
Israel | 5 | 3.0 |
Jews | 5 | 7.0 |
Trinitrotoluene/*adverse effects | 2 | 100.0 |
Binding Sites/genetics | 3 | 0.0 |
Drosophila/genetics | 2 | 1.0 |
Nucleic Acid Conformation | 3 | 0.0 |
Glucosephosphate Dehydrogenase Deficiency/complications/*epidemiology | 5 | 100.0 |
Malaria/complications/*epidemiology/prevention & control | 2 | 100.0 |
Seasons | 2 | 1.0 |
Disease Susceptibility | 5 | 0.0 |
Erythrocytes/enzymology/*parasitology | 7 | 100.0 |
Monocytes/*physiology | 2 | 1.0 |
*Phagocytosis | 5 | 4.0 |
Carcinoma, Hepatocellular/pathology | 2 | 4.0 |
Drug Resistance, Neoplasm/*genetics | 2 | 2.0 |
Liver Neoplasms/pathology | 2 | 4.0 |
Glucose/metabolism | 2 | 0.0 |
Models, Biological | 9 | 0.0 |
Pentosephosphate Pathway/*drug effects | 2 | 100.0 |
*Chromosome Aberrations | 5 | 0.0 |
*Glucosephosphate Dehydrogenase Deficiency/genetics | 2 | 100.0 |
Gene Deletion | 3 | 0.0 |
Antioxidants/metabolism | 3 | 3.0 |
tert-Butylhydroperoxide | 2 | 40.0 |
Glucosephosphate Dehydrogenase Deficiency/complications/*enzymology | 2 | 100.0 |
Jaundice, Neonatal/*enzymology/etiology | 2 | 100.0 |
Computer Simulation | 2 | 0.0 |
*Erythrocyte Transfusion | 2 | 12.0 |
Exons/genetics | 5 | 0.0 |
*Splenectomy | 2 | 6.0 |
Fluorescence | 5 | 1.0 |
Glucosephosphate Dehydrogenase/blood/*metabolism | 4 | 100.0 |
*Polymerase Chain Reaction | 6 | 2.0 |
Pentosephosphate Pathway | 15 | 78.0 |
Bilirubin/blood | 19 | 20.0 |
*African Continental Ancestry Group | 6 | 5.0 |
Erythrocyte Indices | 7 | 11.0 |
Glucosephosphate Dehydrogenase Deficiency/enzymology | 7 | 100.0 |
European Continental Ancestry Group/*genetics | 5 | 1.0 |
Acetylcysteine/*pharmacology | 3 | 13.0 |
Methemoglobin/*metabolism | 3 | 100.0 |
Oxygen/metabolism | 3 | 1.0 |
Oxygen Consumption | 2 | 0.0 |
Fibroblasts/cytology | 2 | 0.0 |
Metaphase | 5 | 3.0 |
*Sex Chromosome Aberrations | 2 | 6.0 |
*Chromosome Mapping | 20 | 1.0 |
DNA Probes | 11 | 1.0 |
*RNA, Untranslated | 3 | 1.0 |
Transcription Factors/genetics | 3 | 0.0 |
Blood Donors | 2 | 0.0 |
Glucosephosphate Dehydrogenase Deficiency/*blood/genetics | 3 | 100.0 |
Haptoglobins/metabolism | 3 | 12.0 |
Hemoglobinometry | 5 | 16.0 |
Glutathione Peroxidase/*metabolism | 3 | 21.0 |
Maleates/pharmacology | 2 | 20.0 |
Sulfhydryl Compounds/*metabolism | 2 | 10.0 |
Neoplasms/blood/*enzymology | 3 | 100.0 |
Anemia, Hemolytic/enzymology/*genetics | 4 | 80.0 |
Electrophoresis, Cellulose Acetate | 9 | 22.0 |
Gene Amplification | 2 | 0.0 |
*Haplotypes | 2 | 0.0 |
Genetic Markers/*genetics | 2 | 1.0 |
India | 17 | 5.0 |
Spain/epidemiology | 3 | 2.0 |
Jaundice, Neonatal/etiology | 5 | 83.0 |
Thalassemia/prevention & control | 2 | 100.0 |
Glucosephosphate Dehydrogenase/*blood/metabolism | 3 | 100.0 |
Glutathione/blood | 19 | 43.0 |
*Heterozygote Detection | 7 | 6.0 |
DNA-Binding Proteins/genetics | 2 | 0.0 |
Gene Expression Regulation, Developmental | 2 | 0.0 |
*Blood Donors | 3 | 2.0 |
Glycogen Storage Disease Type I/*blood/epidemiology | 2 | 100.0 |
Anemia, Hemolytic/*genetics | 2 | 40.0 |
Favism/genetics | 5 | 83.0 |
Chromosome Disorders | 5 | 1.0 |
Karyotyping | 23 | 1.0 |
Leukocytes/*enzymology | 7 | 12.0 |
Brazil | 6 | 2.0 |
Arginine/genetics | 2 | 1.0 |
Point Mutation/*genetics | 5 | 1.0 |
Glucosephosphate Dehydrogenase/chemistry/genetics | 2 | 100.0 |
Oligonucleotide Probes/genetics | 2 | 1.0 |
*Promoter Regions (Genetics) | 4 | 0.0 |
RNA, Messenger/genetics/metabolism | 3 | 0.0 |
Isoelectric Focusing | 8 | 1.0 |
Senegal | 2 | 6.0 |
Discriminant Analysis | 2 | 2.0 |
Gene Pool | 3 | 37.0 |
Mediterranean Islands | 4 | 57.0 |
*Genetic Heterogeneity | 5 | 3.0 |
Sicily/epidemiology | 3 | 37.0 |
African Continental Ancestry Group/genetics | 5 | 1.0 |
DNA/genetics | 19 | 0.0 |
Linkage Disequilibrium | 3 | 0.0 |
Comorbidity | 3 | 1.0 |
*Genetic Vectors | 3 | 0.0 |
*Hematopoietic Stem Cell Transplantation | 2 | 0.0 |
DNA/analysis | 11 | 1.0 |
DNA Replication | 4 | 1.0 |
DNA/blood | 3 | 1.0 |
Nucleic Acid Hybridization | 15 | 0.0 |
Acetylation | 2 | 0.0 |
Fetal Hemoglobin/analysis | 2 | 5.0 |
Leukemia/*blood/enzymology | 2 | 100.0 |
Pyruvate Kinase/blood | 4 | 80.0 |
Medicine, Ayurvedic | 2 | 40.0 |
Length of Stay | 2 | 2.0 |
Postoperative Period | 2 | 0.0 |
Anemia, Hemolytic/blood/*etiology | 2 | 66.0 |
AIDS-Related Opportunistic Infections/*drug therapy | 2 | 7.0 |
Sickle Cell Trait/*epidemiology/genetics | 2 | 100.0 |
Glucosephosphate Dehydrogenase Deficiency/*genetics/*metabolism | 2 | 100.0 |
Blood Cells/enzymology | 4 | 66.0 |
Glucosephosphate Dehydrogenase/*blood/*genetics | 3 | 100.0 |
Glucosephosphate Dehydrogenase Deficiency/blood/enzymology/*genetics | 3 | 100.0 |
Mosaicism | 10 | 14.0 |
*Gene Expression Regulation | 3 | 0.0 |
Regulatory Sequences, Nucleic Acid | 2 | 0.0 |
Tissue Distribution | 2 | 0.0 |
Clone Cells/pathology | 10 | 17.0 |
Colony-Forming Units Assay | 8 | 1.0 |
Glutamate-Cysteine Ligase/deficiency | 2 | 66.0 |
Glutathione Reductase/deficiency | 2 | 100.0 |
Glutathione Synthase/deficiency | 2 | 100.0 |
Alkaline Phosphatase/*metabolism | 2 | 9.0 |
Analysis of Variance | 4 | 0.0 |
Cell Differentiation/drug effects | 2 | 0.0 |
Isoenzymes/*metabolism | 5 | 1.0 |
Rats, Inbred Strains | 2 | 0.0 |
Glucosephosphate Dehydrogenase Deficiency/*enzymology/genetics | 7 | 100.0 |
Spain | 8 | 2.0 |
Hydrogen Peroxide/blood | 2 | 7.0 |
NADP/blood | 8 | 100.0 |
Pyrimidinones/pharmacology | 5 | 41.0 |
Glucosephosphate Dehydrogenase Deficiency/*drug therapy | 2 | 100.0 |
*Apoptosis | 2 | 0.0 |
Acid Phosphatase/blood | 4 | 5.0 |
Blood Glucose/metabolism | 3 | 0.0 |
Sheep | 4 | 0.0 |
Fetal Blood | 2 | 1.0 |
Jaundice, Neonatal/*etiology | 6 | 85.0 |
Africa, Northern | 2 | 13.0 |
Atlantic Islands | 2 | 25.0 |
Chromosome Mapping/*methods | 3 | 1.0 |
Codon | 2 | 0.0 |
Genome, Human | 4 | 0.0 |
*Developing Countries | 2 | 6.0 |
New Guinea | 2 | 18.0 |
Biotransformation | 4 | 0.0 |
Oman | 2 | 22.0 |
Glucosephosphate Dehydrogenase Deficiency/enzymology/genetics | 3 | 100.0 |
Phosphogluconate Dehydrogenase/*blood | 5 | 100.0 |
Glucosephosphate Dehydrogenase Deficiency/blood | 20 | 100.0 |
Energy Metabolism | 2 | 1.0 |
Erythrocytes/*enzymology/metabolism | 3 | 42.0 |
Malaria | 2 | 50.0 |
Pentosephosphate Pathway/physiology | 2 | 100.0 |
Polymorphism, Genetic/genetics | 2 | 0.0 |
Acid Phosphatase/genetics | 5 | 15.0 |
Adenylate Kinase/genetics | 2 | 8.0 |
Africa South of the Sahara | 2 | 13.0 |
Marriage | 2 | 8.0 |
Asia | 2 | 2.0 |
Kernicterus/etiology | 3 | 100.0 |
Point Mutation/genetics | 3 | 1.0 |
Random Allocation | 4 | 0.0 |
Saudi Arabia/epidemiology | 6 | 35.0 |
Electrophoresis, Polyacrylamide Gel/methods | 2 | 1.0 |
Infant, Premature | 2 | 1.0 |
Jaundice, Neonatal/therapy | 2 | 66.0 |
Blood Cells/*enzymology | 2 | 40.0 |
Bone Marrow Cells | 6 | 1.0 |
Clone Cells | 10 | 0.0 |
Hematopoietic Stem Cells/enzymology | 3 | 13.0 |
Models, Genetic | 5 | 0.0 |
Oxidative Stress/*physiology | 2 | 2.0 |
Heat | 14 | 2.0 |
NADP/*metabolism | 7 | 23.0 |
Biological Markers/blood | 3 | 0.0 |
Chloroquine/*adverse effects | 2 | 50.0 |
Erythrocytes/*drug effects | 4 | 18.0 |
Glucosephosphate Dehydrogenase Deficiency/epidemiology/genetics | 2 | 66.0 |
Sickle Cell Trait/epidemiology/genetics | 2 | 66.0 |
Pyruvate Kinase/metabolism | 2 | 11.0 |
Population Surveillance | 5 | 3.0 |
Spectrometry, Fluorescence | 4 | 0.0 |
Blood Proteins/*genetics | 9 | 5.0 |
Membrane Proteins/*genetics | 2 | 0.0 |
Glutathione Reductase/*deficiency | 2 | 100.0 |
Pyruvate Kinase/*deficiency | 4 | 100.0 |
Muscles/*enzymology | 2 | 2.0 |
Leukocytes/enzymology | 10 | 8.0 |
Cluster Analysis | 3 | 1.0 |
Blotting, Southern | 16 | 0.0 |
Recombination, Genetic | 5 | 0.0 |
*Alleles | 10 | 0.0 |
Cell Line, Transformed | 2 | 0.0 |
Exchange Transfusion, Whole Blood | 5 | 45.0 |
Hospitalization | 4 | 3.0 |
Jaundice, Neonatal/*etiology/therapy | 3 | 100.0 |
Haptoglobins/*therapeutic use | 2 | 100.0 |
Medical History Taking | 2 | 5.0 |
Breast Feeding | 3 | 5.0 |
Israel/epidemiology | 2 | 4.0 |
Cholesterol/*blood | 3 | 1.0 |
Lead Poisoning/*metabolism | 2 | 50.0 |
Singapore | 8 | 17.0 |
Cosmids | 3 | 0.0 |
DNA | 3 | 0.0 |
*Genetic Markers | 7 | 2.0 |
Deoxyribonucleases, Type II Site-Specific | 2 | 0.0 |
Hemoglobin, Sickle/genetics | 4 | 40.0 |
Anion Exchange Protein 1, Erythrocyte/*metabolism | 2 | 15.0 |
Hemoglobins | 2 | 6.0 |
Neutrophils/*metabolism | 3 | 1.0 |
*Selection (Genetics) | 3 | 4.0 |
Glucosephosphate Dehydrogenase/*isolation & purification | 4 | 100.0 |
Immunohistochemistry | 4 | 0.0 |
Kernicterus/*etiology | 2 | 100.0 |
Factor VIII/*genetics | 5 | 13.0 |
Catalysis | 3 | 0.0 |
Odds Ratio | 3 | 0.0 |
Regression Analysis | 2 | 0.0 |
Blood Protein Electrophoresis | 8 | 7.0 |
Hemoglobin, Sickle/analysis | 2 | 20.0 |
Malaria, Falciparum/epidemiology | 2 | 100.0 |
DNA/*analysis | 3 | 1.0 |
Molecular Biology | 2 | 0.0 |
Cats | 3 | 0.0 |
Crosses, Genetic | 6 | 0.0 |
Glucosephosphate Dehydrogenase/analysis/genetics | 6 | 85.0 |
*Hematopoiesis | 3 | 1.0 |
Species Specificity | 20 | 0.0 |
Australia | 4 | 2.0 |
Base Composition | 2 | 0.0 |
Anemia, Hemolytic/blood/enzymology/*genetics | 2 | 100.0 |
Malaysia | 8 | 20.0 |
Phosphogluconate Dehydrogenase/blood/*genetics | 2 | 33.0 |
Hemoglobinopathies/*complications/genetics | 2 | 100.0 |
Dermatoglyphics | 2 | 16.0 |
Pyruvate Kinase/blood/*deficiency/genetics | 2 | 66.0 |
Glutathione Peroxidase/*blood | 4 | 23.0 |
Leukemia, Lymphocytic/*enzymology | 3 | 27.0 |
*Gene Expression Regulation, Developmental | 2 | 0.0 |
Enzyme Activation | 9 | 0.0 |
Genetic Predisposition to Disease | 3 | 0.0 |
Malaria/*epidemiology | 5 | 55.0 |
*Carbohydrate Epimerases | 2 | 33.0 |
*Ketone Oxidoreductases | 2 | 66.0 |
Anemia, Hemolytic/enzymology/genetics | 3 | 60.0 |
United States | 8 | 0.0 |
Carrier Proteins/*genetics | 2 | 0.0 |
Anemia, Hemolytic, Congenital Nonspherocytic/*complications | 2 | 100.0 |
Erythrocytes/drug effects/*enzymology | 8 | 40.0 |
Glycogen Storage Disease Type I/*blood | 3 | 75.0 |
Mice, Inbred BALB C | 3 | 0.0 |
Age of Onset | 2 | 0.0 |
Superoxides/metabolism | 2 | 0.0 |
Isoenzymes/analysis | 5 | 8.0 |
Color Vision Defects/genetics | 5 | 55.0 |
Factor IX/genetics | 3 | 14.0 |
*Genetic Predisposition to Disease | 2 | 0.0 |
Genes, Structural | 20 | 2.0 |
Methemoglobin/metabolism | 2 | 28.0 |
Anemia, Hemolytic, Congenital Nonspherocytic/*genetics | 5 | 100.0 |
Algeria | 4 | 23.0 |
*Chromosomes, Artificial, Yeast | 2 | 3.0 |
Dinucleoside Phosphates/*genetics | 2 | 20.0 |
Restriction Mapping | 15 | 0.0 |
Kenya | 4 | 9.0 |
Guinea Pigs | 7 | 0.0 |
Kidney/enzymology | 3 | 2.0 |
Rats, Inbred SHR | 2 | 2.0 |
Circadian Rhythm | 2 | 0.0 |
Leukocytes/*metabolism | 2 | 2.0 |
Exchange Transfusion, Whole Blood/methods | 2 | 100.0 |
Glucosephosphate Dehydrogenase Deficiency/blood/*epidemiology | 3 | 100.0 |
Liver/enzymology | 2 | 0.0 |
Oxidoreductases/*metabolism | 2 | 4.0 |
*Protein Disulfide Reductase (Glutathione) | 2 | 66.0 |
Glucose-6-Phosphate | 4 | 50.0 |
Glucosephosphates/metabolism | 6 | 66.0 |
*Plants, Medicinal | 3 | 4.0 |
Chromosome Deletion | 4 | 0.0 |
*Chromosome Fragility | 2 | 1.0 |
Double-Blind Method | 3 | 0.0 |
Malondialdehyde/blood | 4 | 6.0 |
*Ethnic Groups | 9 | 8.0 |
Adenylate Kinase/blood/*deficiency | 2 | 66.0 |
Anemia, Hemolytic, Congenital/enzymology/etiology/*genetics | 2 | 100.0 |
Recombinant Proteins/isolation & purification/metabolism | 2 | 1.0 |
Alkaline Phosphatase/metabolism | 3 | 2.0 |
Succinate Dehydrogenase/metabolism | 3 | 8.0 |
Electrophoresis, Gel, Pulsed-Field | 3 | 1.0 |
Mice/*genetics | 2 | 0.0 |
Repetitive Sequences, Nucleic Acid | 5 | 0.0 |
*Indians, South American | 2 | 8.0 |
Conserved Sequence | 2 | 0.0 |
Anemia, Hemolytic, Congenital Nonspherocytic/*enzymology/genetics | 5 | 62.0 |
NADP | 9 | 64.0 |
Saccharomyces cerevisiae/genetics | 4 | 0.0 |
Escherichia coli | 2 | 0.0 |
Taiwan | 4 | 2.0 |
Glutathione Disulfide | 5 | 31.0 |
Membrane Proteins/*blood | 3 | 5.0 |
Splenectomy | 5 | 7.0 |
California | 2 | 4.0 |
Coombs' Test | 2 | 7.0 |
DNA/*genetics | 5 | 1.0 |
Diabetes Mellitus, Type 1/*blood/complications | 2 | 15.0 |
Hemoglobin A, Glycosylated/*analysis | 2 | 0.0 |
Blood Specimen Collection | 3 | 6.0 |
Lead/blood | 2 | 15.0 |
*Occupational Exposure | 2 | 1.0 |
Anemia, Sickle Cell/*complications | 3 | 21.0 |
Klinefelter Syndrome/genetics | 2 | 50.0 |
Sex Chromosome Aberrations/*genetics | 7 | 11.0 |
Ascorbic Acid/pharmacology | 2 | 3.0 |
Glutathione/*pharmacology | 2 | 18.0 |
Hydroxylation | 2 | 0.0 |
Hepatitis, Viral, Human/diagnosis | 2 | 66.0 |
Fetal Blood/chemistry | 2 | 3.0 |
Culture Techniques | 4 | 0.0 |
Phosphofructokinase-1/metabolism | 2 | 8.0 |
Oxygen/*blood | 3 | 6.0 |
Superoxide Dismutase/blood | 2 | 4.0 |
Breast Neoplasms | 2 | 0.0 |
Cell Division/*drug effects | 2 | 0.0 |
Smoking | 2 | 0.0 |
Laos/ethnology | 2 | 33.0 |
Philippines/ethnology | 3 | 37.0 |
*Transfection | 2 | 0.0 |
Hydroxysteroid Dehydrogenases/metabolism | 3 | 42.0 |
Staining and Labeling | 8 | 1.0 |
DNA/biosynthesis | 2 | 0.0 |
Proteins/metabolism | 2 | 0.0 |
Biological Markers/analysis | 3 | 0.0 |
Hyperbilirubinemia/*etiology | 2 | 66.0 |
*Phototherapy | 3 | 42.0 |
Hybrid Cells/*enzymology | 2 | 13.0 |
Erythrocyte Membrane/enzymology | 3 | 18.0 |
Hydrogen Peroxide/*pharmacology | 2 | 3.0 |
DNA/chemistry | 2 | 0.0 |
*Trisomy | 3 | 2.0 |
RNA, Messenger/*genetics | 3 | 0.0 |
DNA, Single-Stranded/genetics | 2 | 5.0 |
Oligodeoxyribonucleotides | 4 | 0.0 |
DNA/genetics/isolation & purification | 2 | 0.0 |
Blood Transfusion/*adverse effects | 3 | 4.0 |
Bipolar Disorder/*genetics | 2 | 1.0 |
Cricetulus | 7 | 1.0 |
*Cell Transformation, Neoplastic | 2 | 0.0 |
Fibroblasts/enzymology | 9 | 4.0 |
Aneuploidy | 4 | 2.0 |
Glucosephosphate Dehydrogenase Deficiency/*blood/epidemiology/genetics | 2 | 100.0 |
Iron/*blood | 2 | 5.0 |
Glutathione/analogs & derivatives/*blood | 3 | 60.0 |
Jaundice, Neonatal/*complications | 2 | 100.0 |
Cell Fusion | 3 | 1.0 |
Glucosephosphate Dehydrogenase/biosynthesis | 3 | 75.0 |
Muscles/*enzymology/ultrastructure | 2 | 100.0 |
Isoenzymes/*analysis | 4 | 8.0 |
Clone Cells/enzymology | 5 | 55.0 |
Calpain/pharmacology | 2 | 33.0 |
Favism/*blood | 6 | 100.0 |
Chromosome Banding | 10 | 1.0 |
Evolution | 4 | 1.0 |
Translocation, Genetic | 8 | 1.0 |
Fructose-Bisphosphate Aldolase/blood | 2 | 50.0 |
Hexokinase/blood | 7 | 87.0 |
Cross Reactions | 3 | 0.0 |
Plasmids | 6 | 0.0 |
Protein Biosynthesis | 6 | 0.0 |
Greece/ethnology | 3 | 15.0 |
Chromosomes, Fungal | 3 | 4.0 |
*Polymorphism, Restriction Fragment Length | 8 | 1.0 |
Gene Library | 2 | 0.0 |
Multigene Family | 3 | 0.0 |
2,3-Diphosphoglycerate | 2 | 14.0 |
Blood Glucose/*metabolism | 2 | 0.0 |
Kernicterus/etiology/*prevention & control | 2 | 100.0 |
Glucosephosphate Dehydrogenase Deficiency/*complications/epidemiology | 7 | 100.0 |
Saudi Arabia | 9 | 21.0 |
Malaria/genetics | 3 | 75.0 |
Electrophoresis, Starch Gel | 32 | 23.0 |
Cell Separation | 5 | 0.0 |
Africa, Southern | 2 | 18.0 |
Deoxyribonucleases, Type II Site-Specific/*metabolism | 2 | 8.0 |
Favism/enzymology/genetics | 2 | 100.0 |
Lens, Crystalline/*enzymology | 4 | 30.0 |
Genes, Recessive | 3 | 0.0 |
Hemophilia A/*diagnosis/genetics | 2 | 18.0 |
Lymphocytes/cytology | 2 | 2.0 |
Chromatography, Ion Exchange | 5 | 1.0 |
Glucosephosphate Dehydrogenase/blood/*isolation & purification | 2 | 100.0 |
Glucosephosphate Dehydrogenase Deficiency/blood/enzymology | 4 | 100.0 |
Glucosephosphate Dehydrogenase Deficiency/blood/*complications/genetics | 6 | 100.0 |
Venezuela | 3 | 9.0 |
Infant, Low Birth Weight | 2 | 7.0 |
DNA Restriction Enzymes | 10 | 2.0 |
Prenatal Diagnosis/*methods | 2 | 1.0 |
Glucosephosphate Dehydrogenase/chemistry/*genetics/metabolism | 2 | 100.0 |
Catalase/*blood | 3 | 33.0 |
Glucosephosphate Dehydrogenase Deficiency/blood/enzymology/genetics | 4 | 100.0 |
Oligonucleotides/chemistry | 2 | 1.0 |
Blood | 2 | 1.0 |
Administration, Oral | 2 | 0.0 |
Glucosephosphate Dehydrogenase/*immunology | 2 | 100.0 |
Repressor Proteins/genetics | 2 | 1.0 |
Staining and Labeling/*methods | 2 | 10.0 |
Ascorbic Acid/*pharmacology | 2 | 6.0 |
Copper/*pharmacology | 2 | 11.0 |
Ferric Compounds/*pharmacology | 2 | 28.0 |
Glucosephosphate Dehydrogenase/antagonists & inhibitors | 3 | 100.0 |
Costa Rica | 3 | 23.0 |
Deferoxamine/*pharmacology | 2 | 25.0 |
Fibroblasts/*metabolism | 2 | 1.0 |
Malate Dehydrogenase/*metabolism | 2 | 100.0 |
Phosphogluconate Dehydrogenase/*metabolism | 3 | 75.0 |
Genes, Dominant | 2 | 0.0 |
*Pregnancy Complications | 2 | 5.0 |
Erythrocytes/drug effects/*metabolism | 4 | 20.0 |
Glutathione Reductase/*metabolism | 2 | 50.0 |
Electrophoresis, Agar Gel | 3 | 0.0 |
Polymerase Chain Reaction/*methods | 2 | 0.0 |
Fetus | 2 | 0.0 |
Anemia, Sickle Cell/*genetics | 4 | 44.0 |
Thalassemia/*genetics | 4 | 19.0 |
Glucosephosphate Dehydrogenase/*analysis/genetics | 3 | 100.0 |
Breast Neoplasms/*enzymology | 5 | 7.0 |
Sudan | 7 | 38.0 |
Lymphocytes/*enzymology | 5 | 6.0 |
Paris | 3 | 33.0 |
Glucosephosphate Dehydrogenase/blood/classification/*genetics | 2 | 100.0 |
Ploidies | 2 | 0.0 |
Jaundice, Neonatal/epidemiology/*etiology | 3 | 100.0 |
Anemia, Hemolytic/blood | 3 | 37.0 |
Erythrocyte Aging | 9 | 29.0 |
Povidone | 2 | 40.0 |
Pyruvate Kinase/blood/*deficiency | 2 | 66.0 |
Reticulocytes/enzymology | 4 | 40.0 |
Silicon Dioxide | 2 | 12.0 |
Asia, Southeastern | 2 | 10.0 |
Genes | 8 | 3.0 |
Hemoglobin, Sickle/*genetics | 3 | 42.0 |
Mediterranean Sea | 2 | 28.0 |
Middle East | 2 | 16.0 |
Cell-Free System | 2 | 0.0 |
Erythrocyte Membrane/*physiology | 2 | 15.0 |
Glyceraldehyde-3-Phosphate Dehydrogenases/*blood | 2 | 66.0 |
Anemia, Hemolytic/*enzymology/genetics | 3 | 60.0 |
Fragile X Syndrome/genetics | 2 | 6.0 |
Biopsy | 5 | 0.0 |
Mexico/epidemiology | 2 | 6.0 |
Urban Population | 3 | 2.0 |
Muridae | 2 | 1.0 |
*Diseases in Twins | 2 | 6.0 |
Hemolysis/*physiology | 2 | 25.0 |
Hyperbilirubinemia/etiology | 5 | 100.0 |
Plasmodium falciparum/*enzymology/growth & development | 2 | 100.0 |
Phosphogluconate Dehydrogenase/genetics | 3 | 11.0 |
Cell Survival | 5 | 0.0 |
Fragile X Syndrome/*genetics | 2 | 1.0 |
Hybrid Cells/cytology | 2 | 6.0 |
*Mass Screening | 3 | 5.0 |
ABO Blood-Group System | 3 | 4.0 |
Thalassemia/*complications | 2 | 66.0 |
Deoxyribonuclease HpaII | 3 | 4.0 |
Meiosis | 2 | 1.0 |
*Heterozygote | 8 | 2.0 |
Mental Retardation/*genetics | 2 | 0.0 |
Cross-Sectional Studies | 6 | 0.0 |
Anemia, Hemolytic/*blood/etiology | 2 | 66.0 |
Erythrocytes/enzymology/metabolism | 3 | 33.0 |
*Deoxyribonucleases, Type II Site-Specific | 3 | 4.0 |
Anemia, Hemolytic, Congenital Nonspherocytic/etiology/*genetics | 2 | 100.0 |
*Mosaicism | 4 | 7.0 |
DNA Restriction Enzymes/diagnostic use | 3 | 8.0 |
*Erythrocyte Aging | 7 | 31.0 |
Glucosephosphate Dehydrogenase Deficiency/*genetics/metabolism | 2 | 100.0 |
Chromatography | 2 | 1.0 |
Proto-Oncogene Proteins/*genetics | 2 | 0.0 |
*Proto-Oncogenes | 2 | 0.0 |
Adenosine Triphosphate/metabolism | 3 | 0.0 |
Carbohydrates/*metabolism | 2 | 5.0 |
Malaria/*blood/complications | 2 | 66.0 |
Hematopoietic Stem Cells/enzymology/*pathology | 2 | 66.0 |
Hemoglobin A2/analysis | 2 | 7.0 |
DNA/*metabolism | 3 | 0.0 |
Color Vision Defects/*genetics | 4 | 40.0 |
Plasmodium falciparum/*drug effects/growth & development | 2 | 50.0 |
Glucosephosphate Dehydrogenase/*blood/isolation & purification | 4 | 100.0 |
Isoenzymes/*blood/isolation & purification | 2 | 33.0 |
*Philadelphia Chromosome | 2 | 2.0 |
Hela Cells/*enzymology | 2 | 66.0 |
*Genes, Structural | 15 | 1.0 |
Fatty Acids/*metabolism | 2 | 2.0 |
Glucosephosphate Dehydrogenase Deficiency/blood/*diagnosis | 2 | 100.0 |
Glutathione Reductase/antagonists & inhibitors | 2 | 100.0 |
B-Lymphocytes/*enzymology | 2 | 10.0 |
T-Lymphocytes/enzymology | 2 | 5.0 |
Electrophoresis, Agar Gel/methods | 2 | 8.0 |
Enzymes/*deficiency/genetics | 2 | 100.0 |
Nucleotides/metabolism | 2 | 5.0 |
Hemoglobins, Abnormal/genetics | 2 | 66.0 |
Turkey | 9 | 6.0 |
Cataract Extraction | 2 | 14.0 |
Ecology | 2 | 22.0 |
West Indies | 2 | 25.0 |
Anemia, Hemolytic/*complications | 2 | 100.0 |
Erythrocytes/ultrastructure | 2 | 25.0 |
*Heinz Bodies | 2 | 100.0 |
Centrifugation, Density Gradient | 4 | 1.0 |
Hydroxyl Radical | 2 | 6.0 |
Carbon Radioisotopes | 2 | 2.0 |
Plasmodium falciparum/drug effects/*growth & development | 3 | 75.0 |
Glucosephosphate Dehydrogenase Deficiency/*parasitology | 4 | 100.0 |
Phenylhydrazines/pharmacology | 3 | 37.0 |
Chromatography, Thin Layer | 2 | 1.0 |
Spectrum Analysis, Mass | 2 | 0.0 |
Glucose/pharmacology | 2 | 1.0 |
Superoxide Dismutase/*blood | 3 | 11.0 |
*Genes | 6 | 2.0 |
Hybrid Cells/ultrastructure | 2 | 7.0 |
Mink/*genetics | 2 | 22.0 |
X Chromosome/*ultrastructure | 4 | 16.0 |
Kidney Tubules/*enzymology | 3 | 50.0 |
Kidney Tubules, Distal/*enzymology | 2 | 100.0 |
Parathyroid Hormone/*pharmacology | 3 | 10.0 |
Peptide Fragments/*pharmacology | 2 | 1.0 |
Anemia, Hemolytic, Congenital/*enzymology | 5 | 55.0 |
Tumor Stem Cells/*pathology | 2 | 7.0 |
Alabama | 2 | 18.0 |
Clinical Trials | 3 | 0.0 |
*Colony-Forming Units Assay | 2 | 16.0 |
Hypoxanthine Phosphoribosyltransferase/*genetics | 4 | 8.0 |
Hybrid Cells/enzymology | 6 | 11.0 |
Glucosephosphate Dehydrogenase Deficiency/drug therapy/*enzymology | 2 | 100.0 |
Half-Life | 4 | 0.0 |
Propionates/*adverse effects | 2 | 100.0 |
African Continental Ancestry Group | 15 | 5.0 |
Methods | 6 | 2.0 |
Cats/genetics | 2 | 100.0 |
Free Radicals | 3 | 1.0 |
Flavin-Adenine Dinucleotide/blood | 2 | 100.0 |
Superoxides/*metabolism | 2 | 2.0 |
Glucose-6-Phosphate Isomerase/deficiency/*genetics | 2 | 100.0 |
DNA Restriction Enzymes/metabolism | 3 | 3.0 |
Muscular Dystrophies/*genetics | 3 | 3.0 |
*Recombination, Genetic | 4 | 1.0 |
Chromates/pharmacology | 2 | 100.0 |
*Erythrocytes | 2 | 11.0 |
Jaundice, Neonatal/*enzymology | 2 | 100.0 |
Mutagenicity Tests | 2 | 1.0 |
Azacitidine/*pharmacology | 2 | 12.0 |
Cuba | 3 | 25.0 |
Glycogen Storage Disease Type I/*epidemiology | 2 | 100.0 |
Acid Phosphatase/metabolism | 3 | 4.0 |
Isoenzymes/metabolism | 5 | 0.0 |
Anemia, Hemolytic, Congenital Nonspherocytic/*enzymology | 6 | 85.0 |
Isoenzymes/blood/*genetics | 4 | 18.0 |
Hematopoietic Stem Cells/*enzymology | 3 | 9.0 |
Leukemia, Myeloid/*enzymology | 2 | 25.0 |
Plasmodium falciparum/*enzymology | 2 | 15.0 |
Digoxin/immunology | 2 | 66.0 |
Na(+)-K(+)-Exchanging ATPase/*antagonists & inhibitors | 4 | 22.0 |
Antibodies, Monoclonal | 2 | 0.0 |
Radioimmunoassay | 2 | 0.0 |
Thalassemia/enzymology | 2 | 100.0 |
Benzo(a)pyrene/*metabolism | 3 | 33.0 |
Haptoglobins/genetics | 2 | 4.0 |
Phosphoglucomutase/genetics | 3 | 6.0 |
Transferrin/genetics | 3 | 6.0 |
Membrane Proteins/blood | 2 | 5.0 |
Phosphogluconate Dehydrogenase/*genetics | 2 | 16.0 |
Glycogen Storage Disease Type I/*complications | 2 | 66.0 |
Togo | 2 | 50.0 |
Erythrocytes/pathology | 2 | 12.0 |
Heinz Bodies/pathology | 3 | 100.0 |
Methemoglobinemia/chemically induced | 2 | 50.0 |
Leukocyte Count | 2 | 0.0 |
Erythrocytes/analysis | 2 | 8.0 |
Anemia, Sickle Cell/*epidemiology | 2 | 100.0 |
Glucosephosphate Dehydrogenase Deficiency/*epidemiology/genetics | 4 | 100.0 |
Antigen-Antibody Reactions | 2 | 0.0 |
Hybrid Cells/physiology | 3 | 11.0 |
X Chromosome/*physiology | 6 | 46.0 |
*DNA Replication | 3 | 1.0 |
Malaria/enzymology | 3 | 75.0 |
Papua New Guinea | 2 | 8.0 |
Erythrocyte Membrane/metabolism | 6 | 10.0 |
Antibodies, Monoclonal/diagnostic use | 2 | 0.0 |
Rosette Formation | 3 | 0.0 |
Mutagens/metabolism | 3 | 11.0 |
Hemoglobins, Abnormal/analysis | 3 | 27.0 |
Immunologic Techniques | 2 | 0.0 |
Isoenzymes/blood | 3 | 4.0 |
Erythrocytes | 3 | 6.0 |
Leukemia, Lymphocytic/*blood | 2 | 28.0 |
Skin/enzymology | 3 | 9.0 |
Haptoglobins/*genetics | 2 | 5.0 |
Hemoglobins, Abnormal/*genetics | 2 | 10.0 |
5'-Nucleotidase | 4 | 18.0 |
Glucose-6-Phosphate Isomerase/deficiency | 2 | 66.0 |
Nucleotidases/deficiency | 2 | 100.0 |
Pyruvate Kinase/deficiency | 3 | 60.0 |
Pyrimidinones/*pharmacology | 2 | 22.0 |
Phosphoglycerate Kinase/metabolism | 2 | 66.0 |
Blood Platelets/*enzymology | 3 | 4.0 |
Clone Cells/cytology | 2 | 10.0 |
Azerbaijan | 4 | 57.0 |
*Diabetes Complications | 3 | 5.0 |
Anemia, Hemolytic/enzymology | 4 | 57.0 |
Statistics | 2 | 0.0 |
*Nuclear Warfare | 2 | 15.0 |
Isoenzymes | 4 | 2.0 |
HLA Antigens/genetics | 2 | 0.0 |
Natriuretic Agents | 2 | 100.0 |
*Glucosephosphate Dehydrogenase | 9 | 100.0 |
Glucosephosphate Dehydrogenase Deficiency/*complications/enzymology | 3 | 100.0 |
*Jews | 2 | 4.0 |
Chromosomes, Human, 6-12 and X | 3 | 6.0 |
Trisomy | 2 | 1.0 |
Cell Communication | 2 | 0.0 |
Cytarabine/therapeutic use | 2 | 5.0 |
Daunorubicin/therapeutic use | 2 | 14.0 |
Erythrocyte Membrane/*enzymology | 2 | 6.0 |
Peroxidases/*blood | 3 | 17.0 |
Erythrocyte Aging/*drug effects | 2 | 66.0 |
Blood Platelets/enzymology | 3 | 6.0 |
Glucosephosphate Dehydrogenase Deficiency/metabolism | 4 | 100.0 |
Hematopoietic Stem Cells/*pathology | 5 | 6.0 |
Depression, Chemical | 2 | 1.0 |
Pentosephosphates/*blood | 2 | 40.0 |
Jaundice, Neonatal/epidemiology | 2 | 100.0 |
Asia, Southeastern/ethnology | 2 | 12.0 |
Bulgaria | 6 | 40.0 |
Anemia, Hemolytic/*enzymology | 2 | 40.0 |
Isoelectric Point | 2 | 1.0 |
Bone Marrow/pathology | 2 | 0.0 |
Collagen/metabolism | 2 | 0.0 |
Leukemia/*pathology | 2 | 4.0 |
Leukemia, Lymphocytic/*pathology | 2 | 10.0 |
Altitude | 2 | 8.0 |
*Rh-Hr Blood-Group System | 3 | 10.0 |
Fibroblasts/drug effects/metabolism | 2 | 1.0 |
NADP/*physiology | 2 | 40.0 |
NADPH-Ferrihemoprotein Reductase/analysis | 2 | 100.0 |
Neoplasms, Experimental/chemically induced | 2 | 18.0 |
Glucosephosphate Dehydrogenase Deficiency/etiology | 3 | 100.0 |
Paratyphoid Fever/complications/*enzymology | 2 | 100.0 |
Typhoid Fever/complications/*enzymology | 2 | 100.0 |
Anemia, Dyserythropoietic, Congenital/*complications | 2 | 100.0 |
Anemia, Hemolytic, Congenital/*complications | 2 | 100.0 |
Bone Marrow/ultrastructure | 2 | 15.0 |
Hemophilia A/epidemiology/*genetics | 2 | 50.0 |
Cyprus/ethnology | 2 | 66.0 |
Thalassemia/*epidemiology | 5 | 83.0 |
Plasmodium falciparum/*growth & development | 2 | 40.0 |
Glucosephosphate Dehydrogenase Deficiency/complications/*metabolism | 2 | 100.0 |
Anemia, Hemolytic/*blood | 5 | 55.0 |
Heinz Bodies | 3 | 75.0 |
Fibroblasts/*enzymology | 2 | 5.0 |
Tanzania | 2 | 6.0 |
*Glucose-6-Phosphate/*analogs & derivatives | 2 | 50.0 |
Granulocytes/enzymology | 2 | 16.0 |
Malate Dehydrogenase/analysis | 2 | 18.0 |
Peptide Hydrolases/analysis | 3 | 2.0 |
Phosphoglucomutase/analysis | 2 | 20.0 |
Disinfectants/*adverse effects | 2 | 50.0 |
Goats | 3 | 3.0 |
*Aging | 2 | 1.0 |
Chromosomes, Human/*physiology | 2 | 40.0 |
Genes, Regulator | 2 | 1.0 |
Steryl-Sulfatase | 2 | 1.0 |
Enzymes/*genetics | 2 | 4.0 |
Rabbits/*genetics | 2 | 12.0 |
Renin/blood | 2 | 0.0 |
Sodium/blood | 2 | 1.0 |
Pentosephosphates/*metabolism | 3 | 50.0 |
*Hemoglobins, Abnormal | 3 | 17.0 |
Erythrocyte Membrane/*ultrastructure | 2 | 28.0 |
Erythrocytes/drug effects/*ultrastructure | 2 | 40.0 |
Hemoglobins/*genetics | 3 | 18.0 |
Mali | 4 | 33.0 |
Africa, Central | 2 | 33.0 |
Glucosephosphate Dehydrogenase Deficiency | 2 | 100.0 |
Isoenzymes/*genetics/metabolism | 2 | 3.0 |
*Phenotype | 4 | 1.0 |
Antibodies | 2 | 0.0 |
Anemia, Sickle Cell/genetics | 2 | 100.0 |
*Sex Chromosomes | 15 | 48.0 |
Hexosephosphates/blood | 4 | 100.0 |
Epidemiology, Molecular | 2 | 2.0 |
*Cell Line | 2 | 4.0 |
Erythrocytes/*analysis | 2 | 4.0 |
Spherocytosis, Hereditary/blood | 2 | 100.0 |
Glucosephosphate Dehydrogenase/analysis/*genetics | 2 | 100.0 |
Glucose-6-Phosphate Isomerase/*deficiency | 2 | 28.0 |
Italy/ethnology | 2 | 5.0 |
Sex Chromosomes/*physiology | 3 | 60.0 |
Sulfatases/*genetics | 2 | 10.0 |
Intestinal Absorption | 2 | 1.0 |
Jamaica | 2 | 9.0 |
Chromosome Aberrations/genetics | 2 | 1.0 |
France | 4 | 1.0 |
Cameroon | 2 | 9.0 |
Cholinesterases/blood | 2 | 9.0 |
Phosphoglucomutase/blood | 4 | 25.0 |
Filtration | 2 | 4.0 |
Glucosephosphate Dehydrogenase Deficiency/*diagnosis/enzymology | 2 | 100.0 |
Sicily | 2 | 10.0 |
*Chromosomes, Human, 6-12 and X | 3 | 2.0 |
Hybrid Cells/*ultrastructure | 2 | 33.0 |
Gambia | 2 | 5.0 |
Diphosphoglyceric Acids/*blood | 2 | 40.0 |
South Africa | 2 | 1.0 |
L-Lactate Dehydrogenase/genetics | 2 | 13.0 |
Aspartate Aminotransferases/blood | 4 | 3.0 |
Hemoglobinopathies/*epidemiology | 2 | 66.0 |
Thalassemia/epidemiology | 2 | 50.0 |
Glucosephosphates | 2 | 100.0 |
Electrophoresis, Disc | 2 | 8.0 |
Fluorometry | 3 | 4.0 |
Blood Group Antigens | 2 | 5.0 |
*Chromosomes, Human, 1-3 | 2 | 3.0 |
*Phosphoglycerate Kinase | 5 | 100.0 |
Sex Chromosomes | 7 | 35.0 |
Chemistry | 3 | 1.0 |
Drug Stability | 3 | 1.0 |
Switzerland | 2 | 2.0 |
*Circadian Rhythm | 3 | 1.0 |
Byelarus | 2 | 40.0 |
Ukraine | 2 | 7.0 |
Chromosomes | 3 | 3.0 |
Hypoxanthine Phosphoribosyltransferase/analysis | 2 | 100.0 |
Phosphoglycerate Kinase/analysis | 2 | 100.0 |
Kidney Failure, Acute/*etiology | 2 | 33.0 |
Niridazole/*adverse effects/therapeutic use | 2 | 100.0 |
*Chromosomes, Human, 13-15 | 3 | 10.0 |
Mannose | 2 | 25.0 |
Acid Phosphatase/*blood | 2 | 1.0 |
Deer | 3 | 30.0 |
L-Lactate Dehydrogenase/analysis | 3 | 7.0 |
Texas | 2 | 5.0 |
Lymphocytes/enzymology | 2 | 2.0 |
*ABO Blood-Group System | 2 | 5.0 |
Genetics, Medical | 2 | 8.0 |
*Pentosyltransferases | 2 | 66.0 |
Artiodactyla | 2 | 100.0 |
Carnivora | 3 | 42.0 |
Haplorhini | 3 | 1.0 |
Horses | 3 | 2.0 |
Immunodiffusion | 3 | 1.0 |
Perissodactyla | 2 | 66.0 |
Starch | 3 | 75.0 |
Yugoslavia | 2 | 11.0 |
*Methemoglobin | 2 | 33.0 |
Favism/*enzymology | 2 | 100.0 |
Antimalarials/*pharmacology | 2 | 7.0 |
